Are you Dr. Johnson?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 32 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
201 North Broadway Street
Viragh BLDG 5th FL
Baltimore, MD 21287
Summary
- Dr. Burles Johnson III, MD is an oncologist in Baltimore, Maryland. He is currently licensed to practice medicine in Maryland and Pennsylvania. He is affiliated with Johns Hopkins Hospital.
Education & Training
- Medical College of GeorgiaResidency, Internal Medicine, 2012 - 2015
- Medical College of Georgia at Augusta UniversityClass of 2012
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- MD State Medical License 2015 - 2026
- PA State Medical License 2024 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Nectin-4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study.Ezra G Baraban, Evangelia Vlachou, Sunil Patel, Max Kates, Burles Johnson
The Prostate. 2025-01-02 - NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA.Akhilesh Mishra, Ajay Kumar Sharma, Kuldeep Gupta, Dhanush R Banka, Burles A Johnson
Biorxiv. 2024-12-25 - 3 citationsEnfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience.Evangelia Vlachou, Burles Avner Johnson, David McConkey, Yuezhou Jing, Andres Matoso
Frontiers in Oncology. 2024-01-01